PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

REC'D **1 8 APR 2001**

WIPO   PCT

Applicant's or agent's file reference	**FOR FURTHER ACTION**	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
DC-0120		

International application No.	International filing date *(day/month/year)*	Priority date *(day/month/year)*
PCT/US99/26610	10 November 1999 (10.11.1999)	30 November 1998 (30.11.1998)

International Patent Classification (IPC) or national classification and IPC
IPC(7): C12Q 1/68; C07H 21/04 and US Cl.: 435/6; 536/23.1

Applicant
TRUSTEES OF DARTMOUTH COLLEGE

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 4 sheets, including this cover sheet.

    ☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

    These annexes consist of a total of O sheets.

3. This report contains indications relating to the following items:

    I ☒ Basis of the report

    II ☐ Priority

    III ☐ Non-establishment of report with regard to novelty, inventive step and industrial applicability

    IV ☐ Lack of unity of invention

    V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

    VI ☐ Certain documents cited

    VII ☐ Certain defects in the international application

    VIII ☒ Certain observations on the international application

Date of submission of the demand	Date of completion of this report

Name and mailing address of the IPEA/US	Authorized officer
Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	**TERRY J. DEY** Jeanine Enewold Goldberg **PARALEGAL SPECIALIST**
Facsimile No. (703)305-3230	Telephone No. (703) 308-0656 **TECHNOLOGY CENTER 1600**

Form PCT/IPEA/409 (cover sheet)(July 1998)

I. Basis of the report

1. With regard to the **elements** of the international application:*

   ☒ the international application as originally filed.

   ☒ the description:
   pages 1-13 as originally filed
   pages NONE , filed with the demand
   pages NONE , filed with the letter of _____.

   ☒ the claims:
   pages 14 , as originally filed
   pages NONE , as amended (together with any statement) under Article 19
   pages NONE , filed with the demand
   pages NONE , filed with the letter of _____.

   ☐ the drawings:
   pages NONE , as originally filed
   pages NONE , filed with the demand
   pages NONE , filed with the letter of _____.

   ☒ the sequence listing part of the description:
   pages 1-5 , as originally filed
   pages NONE , filed with the demand
   pages NONE , filed with the letter of _____.

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.
   These elements were available or furnished to this Authority in the following language _____ which is:

   ☐ the language of a translation furnished for the purposes of international search (under Rule23.1(b)).

   ☐ the language of publication of the international application (under Rule 48.3(b)).

   ☐ the language of the translation furnished for the purposes of international preliminary examination(under Rules 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

   ☒ contained in the international application in printed form.

   ☒ filed together with the international application in computer readable form.

   ☐ furnished subsequently to this Authority in written form.

   ☐ furnished subsequently to this Authority in computer readable form.

   ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

   ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☒ The amendments have resulted in the cancellation of:

   ☒ the description, pages none

   ☒ the claims, Nos. none

   ☒ the drawings, sheets/fig none

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

   * *Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).*
   ** *Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.*

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. STATEMENT

Novelty (N)	Claims 1-5	YES
	Claims NONE	NO
Inventive Step (IS)	Claims 1-5	YES
	Claims NONE	NO
Industrial Applicability (IA)	Claims 1-5	YES
	Claims NONE	NO

2. CITATIONS AND EXPLANATIONS (Rule 70.7)

Claims 1-5 meet the criteria set out in PCT Article 33(2)-(4), because the prior art does not teach or fairly suggest a method of diagnosing a matrix metalloproteinase-1 related disease in a patient comprising detecting in the patient matrix metalloproteinase-1 containing the Ets transcription factor binding site single nucleotide polymorphism.

-------------------- NEW CITATIONS --------------------

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the questions whether the claims are fully supported by the description, are made:

Claims 1-5 are objected to as lacking clarity under PCT Rule 66.2(a)(v) because practice of the claimed invention is not enabled as required under PCT Rule 5.1(a) for the reasons set forth in the immediately preceding paragraph.

The claims are broadly drawn to a method of diagnosing or prognosticating a matrix metalloproteinase-1 related disease by detecting the matrix metalloproteinase-1 (MMP-1) containing the Ets transcription factor binding site single nucleotide polymorhism. The claims are also drawn to methods of identifying therapeutic agents for treatment of a MMP-1 related disease.

The specification teaches MMP-1 is associated with irreversible degradation of cartilage, tendon and bone in arthritis, degradation of collagenase I and III in tumor invasion and metastasis (pg. 1). Furthermore, the specification teaches that patients with tumors that express MMP-1 have a poor prognosis than patients with tumors that do not express this protein (pg. 2). The specification teaches that the full length DNA sequence with only 1 G at position –1607 constitutes a SNP (pg. 3). The specification teaches that while the SNP is not located in the coding region and does not alter the structure of the enzyme, it has profound effect on the production/regulation of the enzyme (pg. 4). The specification further teaches a study in which 100 hundred control DNA's were sampled to determine the frequency of the variation in the population (pg. 8). The specification teaches that the frequency of the 2G homozygotes in the controls was approximately 30% whereas the frequency in tumor cell lines was 62.5% ($p < 0.0001$) (pg. 8). The specification provides several explanations which may explain the differences in expression such as growth factor and cytokines, specific nuclear factors within the cell (pg. 9).

The art teaches the a DNA sequence of the MMP-1 which only contained 1G at position –1607 (Rutter et al. J. Cell Biochem. 66: 322-336, 1997)(pg. 2). The art also teaches the sequence where 2Gs are located at this position (pg. 2). The consnsus sequence for a functional PEA3/EBS is provided in Graves (J.B. Science 279: 1000-1001, 1998).

It would be undue experimentaiton for the skilled artisan to practice the invention as broadly as claimed. The assertion that the MMP-1 EBS-SNP in patients is indicative of the patient suffering from a disease relating to overexpression of the MMP-1 enzyme is not supported by any clinical studies that provide this correlation. While the specification teaches that the frequency of the 2G homozygotes is expressed more frequency in tumor cell lines, this does not provide enablement for a method of diagnosing a MMP-1 related disease based upon the identification of the SNP. The study does not provide any data taken from patients with MMP-1 disesaes, but rather amples cell lines. Cell lines are not representative of individuals with MMP-1 related diseases. Secondarily, the specification does not identify any specific disease which have been shown to be associated with the 2G polymorphism in the MMP-1. It would be undue experimentation for the skilled artisan to perform clinical studies to associate the single nucleotide polymorphism with a MMP-1 related disease. Additionally, the specification provides several plausible explanations as to the difference in expression. Thus, it is unpredictable whether the 2G polymorphism is associated with MMP-1 diseases or whether extrinsic factors affect the expression and disease characteristics.

09/856749

PCT/US99/26610

531 Rec'd PCT/PT 24 MAY 2001

Methods of Diagnosing, Prognosticating and Treating Matrix
Metalloproteinase-1 Related Diseases via a Matrix
Metalloproteinase-1 Single Nucleotide Polymorphism

INTRODUCTION

5   This invention was made in the course of research
sponsored by the National Institutes of Health. The U.S.
Government may have certain rights in this invention.

BACKGROUND OF THE INVENTION

10   Matrix metalloproteinases (MMPs) are a family of at
least 15 enzymes that degrade the extracellular matrix (ECM)
(Borden, P. and Heller, R. Crit. Rev. Eukaryotic Gene Expr.
7: 159-178, 1997). These enzymes have essential roles in
modeling and remodeling the ECM in normal physiology and
15 disease pathology. Several of these enzymes have the unique
ability to degrade the interstitial collagenase (types I, II,
and III), the body's most abundant proteins. MMP-1 is the
most ubiquitously expressed interstitial collagenase, thereby
assigning it a prominent role in collagen degradation.
20 Overexpression of MMP-1 is associated with several
pathological conditions, including the irreversible
degradation of cartilage, tendon, and bone in arthritis
(Vincenti et al. Crit. Rev. Eukaryotic Gene Expr. 6:391-411,
1996) and the degradation of collagenase I and III in tumor
25 invasion and metastasis (Chambers, A.F. and Matrisian, L.M.
J. Nat'l Cancer Inst. 89:1260-1270, 1997; Murray et al. Nat.

Med. 2:461-462, 1996). Patients with tumors that express MMP-1 have an overall poorer prognosis than patients with tumors that do not express this protein (Murray et al. Nat. Med. 2:461-462, 1996; Murray et al. J. Pathol. 185:256-261, 1998).

5   This overexpression of MMP-1 has been suggested to be due to the juxtaposition of transcription factor binding sites within the promoter of this gene and to the cooperativity among the factors that bind these sites (Buttice et al. Oncogene 13:2297-2306, 1996; Basuyaux et al. J. Biol. Chem. 272:26188-

10   26195, 1997; Gutman, A. and Waslyk, B. EMBO J. 9:2241-2246, 1990; Benbow, U. and Brinckerhoff, C.E. Matrix Biol. 15:519-526, 1997).

Most normal cells express modest, but detectable, levels of MMP-1 constitutively, and this expression increases

15   substantially in the presence of cytokines or growth factors (Vincenti et al. Crit. Rev. Eukaryotic Gene Expr. 6:391-411, 1996; Rutter et al. J. Cell Biochem. 66:322-336, 1997; Aho et al. Eur. J. Biochem. 247:503-510, 1997; Delany, A.M. and Brinckerhoff, C.E. J. Cell Biochem. 50:400-410, 1992).

20   However, A2058 melanoma cells constitutively express high levels of MMP-1 (Templeton et al. Cancer Res. 50:5431-5437, 1990), making them a useful model for studies on the transcriptional regulating of this gene and for comparative studies with normal cells.

25   A 4 kb region of the MMP-1 promoter DNA from a leukocyte genomic library was isolated and sequenced (Rutter et al. J. Cell Biochem. 66:322-336, 1997). DNA sequence analysis revealed that this clone contained only 1 G at position -1607 bp, resulting in the sequence 5'-AAGAT-3' (SEQ ID NO: 1)

30   (Rutter et al. J. Cell Biochem. 66:322-336, 1997). This sequence differs from that reported by others (Aho et al. Eur. J. Biochem. 247:503-510, 1997; Imai et al. Mol. Cell Biol. 14:7182-7194, 1994), wherein 2 Gs at that location which create the sequence 5'-AAGGAT-3' (SEQ ID NO: 2) are

35   described. The presence of 2 Gs at this site creates the

sequence 5'-GGA-3', which is a consensus sequence (Graves, J.B. Science 279:1000-1001, 1998) for a functional PEA3/EBS. This site has now been established to constitute a single nucleotide polymorphism (SNP). The full length DNA sequence

5   of MMP-1 with only 1 G at position -1607 is depicted in SEQ ID NO: 3.

Based upon the effect of this SNP on the transcriptional activity, protein/DNA binding activity, and frequency of this SNP in normal fibroblasts and in melanoma tumor cells it has

10 now been determined that detection of this SNP is useful in diagnosing and prognosticating cancer and other MMP-1 related diseases. It is also now believed that agents identified as inhibitors of binding of transcription factors to the Ets transcription factor binding site created by or resulting from

15 this SNP will be useful in treating MMP-1 related diseases.

SUMMARY OF THE INVENTION

An object of the present invention is to provide a method of diagnosing MMP-1 related diseases in a patient which comprises detecting in a patient MMP-1 containing an Ets

20 transcription factor binding site single nucleotide polymorphism (MMP-1 EBS-SNP).

Another object of the present invention is to provide a method of prognosticating MMP-1 related diseases in a patient which comprises detecting in a patient suffering from

25 an MMP-1 related disease an MMP-1 EBS-SNP.

Another object of the present invention is to provide a kit for diagnosis and prognosis of an MMP-1 related disease in a patient via detection of MMP-1 EBS-SNP in a patient sample.

30   Another object of the present invention is to provide a method of identifying agents with potential therapeutic value in treating MMP-1 related diseases which comprises screening agents for the ability to inhibit the binding of a transcription factor to an MMP-1 EBS-SNP.

Yet another object of the present invention is to provide a method of treating MMP-1 related diseases in a patient which comprises administering to the patient an agent which inhibits binding of a transcription factor to an MMP-1
5 EBS-SNP.

DETAILED DESCRIPTION OF THE INVENTION

The abundance of single nucleotide polymorphisms (SNPs) in the genome make these genomic variations powerful tools for
10 identifying disease genes, particularly in loss of heterozygosity studies in tumors. A large effort is presently underway for identifying SNPs. Most research is focused on the coding regions of genes (Wang et al. Science 280:1077-1082, 1998).

15 However, an SNP located in the promoter of the interstitial collagen degrading enzyme, MMP-1, has now been identified. Because this variation is not located in a coding region, it does not alter the structure of the enzyme. However, the location of this SNP in the promoter region of
20 MMP-1 has now been demonstrated to have profound effects on the production/regulation of the enzyme. Further, an increase in the frequency of this SNP in tumor cell lines has now been demonstrated which is indicative of this SNP causing an increase in invasive behavior due to high levels of MMP-1
25 expression. MMP-1 is implicated in tumor cell invasion and metastasis due to its ability to cleave the interstitial collagenase types I and III at neutral pH. Therefore, a structural variation with the potential to influence the level of expression is important to understanding how this enzyme
30 modulates ECM metabolism and tumor cell invasion and metastasis. Further, detection of this SNP in a patient is useful in diagnosing and prognosticating MMP-1 related diseases.

The effects of this SNP, referred to herein as MMP-1
35 EBS-SNP, on the transcriptional activity and protein/DNA

binding activity, along with the frequency of this SNP in normal fibroblasts and in melanoma tumor cells were examined in detail.

Constitutive mRNA expression of endogenous MMP-1 gene
5   in normal foreskin fibroblasts (HFS) and in the A2058 melanoma cells over a 24 hour period was determined. HFS expressed low levels of MMP-1 mRNA, while A2058 cells expressed higher levels. To determine whether the A2058 cells contained a difference in the endogenous MMP-1 promoter, polymerase chain
10   reaction (PCR) was used to amplify the promoter from these cells. This sequence was then compared with the previously isolated leukocyte clone described by Rutter et al. J. Cell Biochem. 66:322-336, 1997 and set forth in SEQ ID NO: 3 and with promoters from other sources (Aho et al. Eur. J. Biochem.
15   247:503-510, 1997; Imai et al. Mol. Cell Biol. 14:7182-7194, 1994).   Several substitutions were observed, but were considered insignificant because they did not create or delete any known binding sites for transcription factors within the promoter. However, one major difference was detected: the
20   A2058 promoter DNA contained an additional G at position -1607 bp, which was flanked by a guanidine (5') and an adenine (3'), thus creating an Ets transcription factor binding site (EBS; Graves, B. Science 279:1000-1001, 1998).

To specifically test the role of the 1 G/2 G variation
25   in regulating transcription, two luciferase reporter constructs driven by a large (4.3 kb) fragment of the MMP-1 promoter were generated with the only difference being 1 G or 2 Gs at -1607 bp. This SNP is adjacent to an AP-1 site -1602 bp, which may also influence transcription. These clones were
30   transitely transfected in HFS and the effect on basal transcription was measured. A significant increase (ranging from 2-10-fold) in transcription with the 2 G promoter construct compared with the 1 G promoter construct was consistently observed in at least four separate donors of HFS.
35   Hirt's analysis of transfected DNA demonstrated that these

differences were not attributable to transfection efficiency.
When these two constructs were transfected into the A2058
melanoma cells, a 29-fold increase in transcription of the 2
G construct over the 1 G construct was observed.   Other
5   experiments showed similar increases ranging from 1- to 37-
fold.   These constructs were then tested in other tumor cell
lines (MDA231 breast cancer cells, and two primary melanoma
lines) to assess their transcriptional response.   In these
cells, the 2 G promoter construct augmented transcription at
10   least 4-fold over the 1 G construct.   Thus, the increase in
transcription is dependent on the presence of 2 Gs at -1607
bp, and it is seen in both normal and malignant cells.

The ability of an oligo probe containing either 1 G or
2 Gs at -1607 bp to bind to nuclear extracts from the A2058
15   cells was also assessed.   A striking difference in binding
intensity was seen, with the 2 G oligo binding more nuclear
proteins compared with the 1 G oligo. Thus, the presence of
the 2 Gs clearly augments this binding.   Cross competition
experiments were used to determine the specificity of binding
20   to each labeled oligo.   Binding to the 1 G oligo was readily
competed, suggesting that these DNA/protein interactions are
weak.   Competition studies with the 2 G oligo revealed that
the "self" oligo only mildly competed the binding of the
shared bands, although it did compete two bands, demonstrating
25   that these proteins bind preferentially and/or specifically
to the 2 G oligo .   Furthermore, the 1 G oligo did not compete
well, but was effective in competing the shared bands.
Finally, the proximal EBS-AP-1 competitor showed a pattern
similar to that seen with the 1 G oligo.   Taken together,
30   these observations indicate that the 2 G "self" oligo competes
for the proteins able to bind specifically to the 2 gene
sequence, and that the other bands represent proteins or
protein complexes that are not 2 G-dependent (e.g. the AP-1
proteins).   Importantly, these data also indicate that the

presence of the EBS in this region of MMP-1 creates an
environment where DNA/protein interactions strongly occur.

Because the SNP at -1607 bp is located adjacent to an
AP-1 site at -1602 bp, binding to the 1 G and 2 G oligos by
5   recombinant ETS-1 and c-JUN, proteins that are likely
candidates for binding to these sites, was investigated. The
recombinant proteins, by themselves, were not able to bind to
either oligo. The combination of both proteins, however,
bound to the 2 G oligo, but only faintly to the 1 G oligo,
10 suggesting that additional proteins were required for optimal
DNA binding. Indeed, incubation with nuclear extract from
A2058 cells resulted in distinctive binding patterns for each
probe. Complexes I, II, VI, and VII were present in both
panels, whereas complexes III, IV, and V were specific for the
15 2 G oligo. When ETS-1 and c-JUN were added together with
nuclear extract, binding to the 2 G oligo was more pronounced
compared with the 1 G oligo.

In the presence of recombinant c-JUN, complex I became
more apparent with both oligos, indicating that complex I may
20 represent AP-1 proteins binding to the DNA. Complex VII also
became more intense when c-JUN was added indicating that it,
too, contains AP-1 related proteins. When both recombinant
proteins were added, the binding pattern in the 1 G panel did
not differ from the reactions with c-JUN alone, supporting the
25 importance of 2 Gs in creating the EBS. When nuclear extracts
and recombinant ETS-1 were added to the 2 G oligo, a new
complex was formed (complex IV). Furthermore, when both
proteins and nuclear extract were added to the 2 G probe,
several complexes (I, III, IV, V, and VI) were diminished and
30 seemed to combine into a much stronger complex II, again
demonstrating the influence of the 2 Gs in creating EBS.

Antibodies to several members of the Ets family of
transcription factors (ETS-1/2, Erg-1/2, Elk-1 and ERM) were
used in "super/shift" reactions to identify the proteins
35 binding to this site. However, binding of these antibodies

was not detected due either to limitations of the antibodies, because the complexes did not allow for the antibody to have access to the epitope, and/or because these proteins did not bind. These data suggest that the oligos containing 2 Gs

5   represents a bona fide EBS that binds an Ets family member(s) in a complex with AP-1 protein members. While the data show that recombinant ETS-1 binds, it is believed that other Ets family members can also bind to this site.

Confirmation of this 1 G/2 G difference in the leukocyte

10 clone sequence and the A2058 melanoma sequence, to be a SNP and not a mutation, was performed. A radiolabeled PCR assay using primers that flank the variation to amplify a product of either 148 bp (1 G), 149 bp (2 G), or both (heterozygous) in genomic DNA was developed. One hundred control DNAs

15 derived from the CEPH pedigrees (http://www.cephb.fr/cephdb/) were then assayed to determine the frequency of this variation within a population. Only the parents in the pedigrees were used to avoid biasing the results through inheritance. In addition to the CEPH control DNAs, the frequency of this SNP

20 in several tumor cell lines, including the A2058 melanoma cells, was assessed. The occurrence of 2 G homozygotes in the CEPH controls was determined to be approximately 30%. In the tumor cells lines, it is 62.5% (P<0.0001).

Accordingly, based upon these experiments, it is

25 believed that the 1 G/2 G SNP influences the transcriptional responsiveness of the human MMP-1 promoter in cancer, where excessive production of MMP-1 is a major contributor to the stromal degradation involved in tumor invasion. As with other genes, expression of MMP-1 is meditated by multiprotein

30 complexes that bind to DNA in a sequence-specific manner, and these complexes often cooperate to achieve maximal activation. DNA elements containing a single EBS are often not sufficient for Ets induction, and require a nearby AP-1 site to which Fos and JUN proteins bind. Furthermore, the transcriptional

35 environment within the cells may influence the level of gene

expression, as evidenced by differences in the level of transcription of the 2 G allele in HFS versus melanoma cells. These differences may be due to various extracellular stimuli, such as growth factors and cytokines, as well as cell-type-
5 specific nuclear factors within the cell. Thus, the combination of cis-acting sequences in the MMP-1 promoter and specific trans-acting factors can dramatically increase transcription. This increase is believed to provide a molecular mechanism for enhanced ECM degradation not only in
10 cancer, but in other MMP-1 related diseases such as arthritis, cardiovascular disease and periodontitis.

For example, rheumatoid arthritis, a chronic disease that afflicts more than two million individuals in the United Stated and 1% of the population world-wide is characterized
15 by severe and irreversible degradation of cartilage, tendon and bone mediated by overexpression of MMPs. Inflammatory cytokines such as interleukin-1 and tumor necrosis factor-α activate synovial fibroblasts that line the joint and adjacent chondrocytes to produce these MMPs. Destruction of
20 interstitial collagen occurs mainly through two MMP family members, MMP-1 and MMP-13. MMP-1 and MMP-13 are expressed by synovial fibroblasts and articular chondrocytes. It is believed that, in similar fashion to patients suffering from cancer, overexpression of MMP-1 in patients suffering from
25 rheumatoid arthritis may result at least in part from this SNP.

Accordingly, detection of the MMP-1 EBS-SNP in a patient provides a useful means for diagnosing MMP-1 related diseases. Detection of MMP-1 EBS-SNP in a patient is indicative of the
30 patient suffering from a disease relating to overexpression of the MMP-1 enzyme. Detection of this SNP can be performed in accordance with well known techniques including, but not limited to, PCR as described herein.

Detection of MMP-1 EBS-SNP also provides a useful method
35 for prognosticating MMP-1 related diseases in a patient. For

example, it is well known that MMPs are key players in tumor invasion and metastasis. Both processes require degradation of the extracellular matrix, which is accomplished by proteolytic enzymes that are secreted by either tumor cells,

5 themselves, and/or neighboring stromal cells. In fact, at least for melanoma cells which produce MMP-1, the prognosis of the disease is correlated with tumor thickness and depth of invasion through dermal collagens (I and II), thereby indicating that invasiveness through these collagens serves

10 as a valid prognostic marker. Accordingly, detection of MMP-1 EBS-SNP, which is indicative of enhanced ability to degrade collagen types I, II and III, in tumor cells of a patient serves as a useful prognostic marker in assessing the invasiveness of a particular tumor. This prognostic marker

15 is thus useful in determining various treatment regimes expected to be most successful in individual patients.

Means for detecting MMP-1 EBS-SNP in a patient sample for diagnosing and/or prognosticating MMP-1 related diseases can be incorporated into a kit for easy use by a laboratory

20 technician. In one embodiment, the kit can comprise PCR primers such as those described in Example 5 herein which flank the MMP-1 EBS SNP. In this embodiment, the kit may also comprise dGTP, dATP, dTTP, and dCTP; Taq DNA polymerase; and $\alpha(32)$P-dCTP. However, other means for detecting the MMP-1

25 EBS-SNP which can be incorporated into a kit will be obvious to those of skill in the art upon this disclsoure. Kits of the present invention may also comprise positive and negative control samples.

Further, inhibiting MMP-1 synthesis by targeting either

30 the MMP-1 EBS-SNP or proteins that bind to this SNP represents a useful therapeutic approach to inhibit pathologic expression of MMP-1, but not its normal physiological role. Potential therapeutic agents for treatment of MMP-1 related diseases including, but not limited to, cancer, rheumatoid arthritis,

35 cardiovascular disease and periodontitis, can be identified

by determining their ability to either bind to MMP-1 EBS-SNP, to bind to proteins which bind to MMP-1 EBS-SNP or to inhibit binding of MMP-1 EBS-SNP with other proteins. Agents identified by this method can then be administered to patients

5 suffering from an MMP-1 related disease to alleviate the symptoms resulting from overexpression of MMP-1.

The following nonlimiting examples are provided to further illustrate the present invention.

EXAMPLES

10 **Example 1: Cells and Plasmids**

Primary human foreskin fibroblasts (HFF) were prepared in accordance with procedures described by Rutter et al. J. Cell Biochem. 66:322-336, 1997, and used during passages 4-8. HFFs and A2058 cells were cultured in DMEM (Life technologies,

15 Inc.) with 10% fetal bovine serum (Sigma Chemical Co.), penicillin (100 units/ml), and streptomycin (100 µg/ml).

A 4.3-kb MMP-1 promoter DNA fragment containing only 1G at -1607 bp was described by Rutter et al. J. Cell Biochem. 66:322-336, 1997. Primers were made to amplify the endogenous

20 promoter from the A2058 cells (-4008 bp to -3988 bp sense primer: 5'-GTGGAAGCTTACACCTATAATCCCAACACTC-3' (SEQ ID NO: 4) and -511 bp to -543 bp antisense primer: 5'-CTGCCTGGTACCCTATTGCGATAGCACCATGGC-3' (SEQ ID NO: 5). Two A2058 PCR amplified clones were subcloned into the pBL5CAT

25 (Promega) vector and sequenced to ensure the absence of PCR artifacts. Reporter clones were then constructed in which the only difference between the two pGL3-MMP-1 vectors was the SNP at position -1607 bp. First, the MMP-1 promoter insert from the pXP2 vector was subcloned into the pGL3 Basic vector

30 (Promega). Unique sequences flanking the G variation were restricted by AatII (5') and EcoRV (3'), thereby isolating a 450/451-bp fragment from the leukocyte clone in pGL3 Basic (1 G) and A2058 melanoma DNA in pBL5CAT (2 Gs), respectively, and excluding any other sequence variations found in the A2058

35 promoter. Finally, the 451-bp insert containing the 2 Gs was

"swapped" and ligated into the pGL3-MMP-1 construct containing AatII/EcoRV ends, thereby generating the two SNP constructs.

Example 2: Northern Analysis

Confluent cultures in 150-mm diameter tissue culture
5 dishes were washed and placed in 10 ml of serum-free DMEM plus 0.2% lactalbumin hydrolysate. Immediately (time 0) and at 24 hours, total RNA was isolated using the TRIzol reagent (Life Technologies, Inc.) and 20 µg were subjected to Northern analysis and hybridized with cDNA-specific probes for MMP-1
10 or glyceraldehyde-3-phosphate dehydrogenase. Probes were random prime labeled with $\alpha(32)$P-dCTP (12.5 µCi/reaction of 3,000 Ci/mmol) and hybridized for 20 hours at 56°C.

Example 3: Transfection and Luciferase Assay

Transient transfections were performed in triplicate in
15 accordance with procedures described by Rutter et al. J. Cell Biochem. 66:322-336, 1997 with the LipofectAMINE PLUS reagent (Life Technologies, Inc.) using 2 µg of the chimeric MMP-1 promoter/reporter plasmids, 5 µl of the PLUS reagent, and 5 µl of LipofectAMINE. Luciferase activity is reported as RLUs.
20 Hirt's analyses were performed and normalized to RLUs to control for any variations in transfection efficiency. Statistics were performed using the InStat Program (GraphPad Software) using the Welch's alternate t test, a modification of the unpaired t test.

25 **Example 4: Nuclear Extract Preparation and EMSAs**

Extracts of nuclear proteins were prepared, and EMSAs were performed as described by Schroen, D.L. and Brinckerhoff, C.E. J. Cell Physiol. 169:320-332, 1996, with 1 x 10^5 cpm of γ^{32}P-ATP end-labeled oligo incubated with nuclear extract (5
30 µg) and/or recombinants ETS-1 protein (2 µM) and c-JUN protein (1 µg; Promega). The samples were subjected to 5% PAGE at 150 V, dried, and autoradiographed. Oligos used for EMSAs were

1G sense, 5'-AAATAATTAGAAAGATATGACTTATCTCAAATCAA-3' (SEQ ID NO: 6); 2 G sense, 5'-AAATAATTAGAAAGGATATGACTTATCTCAAATCAA: (SEQ ID NO: 7) -88/-73 sense, 5'- TTCATTGTTAATCAAGAGGATGTTATAAAGCATGAGTCACACCCTCAGCTT-3' (SEQ ID NO: 8). The -88/-73 oligo spans the region -110 to -61 bp and includes the locations within the oligo that correspond to the proximal PEA3/AP-1 sites at the -88/-73, respectively.

Example 5: Radiolabeled PCR Assay

Primers that flank the SNP in MMP-1 were used for PCR amplification (sense primer, 5'-GTTATGCCACTTAGATGAGG-3' (SEQ ID NO: 9); antisense primer 5'-TTCCTCCCCTTATGGATTCC-3' (SEQ ID NO: 10)). A typical reaction consisted of ~20 ng of DNA template; 0.2 mM dGTP, dATP, and dTTP, 2.5 µM dCTP; 10 x buffer and Taq DNA polymerase (Sigma Chemical Co.); and $\alpha(32)$P-dCTP (DuPont/NEN). Reactions were PCR amplified (MJ Research PTC100 THERMOCYCLER) in 25 cycles (4 minutes at 94°C; 45 seconds at 94°C, 45 seconds at 58°C, and 45 seconds at 72°C; followed by a brief extension (10 minutes) at 72°C). Following amplification, the reactions (2.5 µl) were mixed with 10 X loading buffer and denatured for 2 minutes at 80°C. Samples were loaded onto an 8% denaturing PAGE and electrophoresed for 3 hours. Gels were dried and autoradiographed for approximately 15 minutes. Control samples generated from the plasmid clones were loaded on each gel for accurate scoring of the alleles. Statistics were calculated using the InStat Program (GraphPad Software) and were based on the percentage of the total number tested.

- 14 -

What is claimed is:

     1.   A method of diagnosing a matrix metalloproteinase-1 related disease in a patient comprising detecting in the patient matrix metalloproteinase-1 containing the Ets
5 transcription factor binding site single nucleotide polymorphism.

     2.   A method of prognosticating a matrix metalloproteinase-1 related disease in a patient suffering from a matrix metalloproteinase-1 related disease comprising
10 detecting in the patient matrix metalloproteinase-1 containing the Ets transcription factor binding site single nucleotide polymorphism.

     3.   A kit for diagnosing and prognosticating MMP-1 related diseases in a patient sample comprising a means for
15 detecting matrix metalloproteinase-1 containing the Ets transcription factor binding site single nucleotide polymorphism in a patient sample.

     4.   A method of identifying potential therapeutic agents for treatment of a matrix metalloproteinase-1 related
20 disease comprising determining a potential therapeutic agent's ability to inhibit binding of a transcription factor to an Ets transcription factor binding site of single nucleotide polymorphism matrix metalloproteinase-1.

     5.   A method of treating patients suffering from a
25 matrix metalloproteinase-1 related disease comprising administering to the patient an agent which inhibits binding of a transcription factor to an Ets transcription factor binding site of single nucleotide polymorphism matrix metalloproteinase-1.

SEQUENCE LISTING

<110> Brinckerhoff, Constance
    Rutter, Joni
    Trustees of Dartmouth College

<120> Methods of Diagnosing, Prognosticating and Treating
    Matrix Metalloproteinase-1 Related Diseases via a
    Matrix Metalloproteinase-1 Single Nucleotide
    Polymorphism

<130> DC-0120

<140>
<141>

<150> 60/110,266
<151> 1998-11-30

<160> 10

<170> PatentIn Ver. 2.0

<210> 1
<211> 5
<212> DNA
<213> Homo sapiens

<400> 1
aagat   5

<210> 2
<211> 6
<212> DNA
<213> Homo sapiens

<400> 2
aaggat   6

<210> 3
<211> 4438
<212> DNA
<213> Homo sapiens

<400> 3
cctcacatat ttcaaatcca tctcaaattc acattcacag atgtaagagc tgggaaagga 60
cggttttgac agggctgaac tgagctatgg tatgagtagc actcatcccc agaaagtctc 120
ttggtttgaa tttccgggaa aaggagctat agctgcaaaa atctgtttca caaatgtgct 180

1

```
aactataagc attttccaca gtgtttaata aaccatgcag ataagaaaat attattgaca 240
aacaaattaa taaaatgctc aaaataatct gatactaaat gcttgtagca tggcatgcaa 300
atcaccaaaa ataaatgtgc tatgcttcat ataaaatctc cagtaaggct gggtgtggtg 360
gctcacacct ataatcccaa cactctggga ggccgaggtg agagaactgc ttgaggccag 420
gagtttgaga ctagcctggc caacatagtg agacctcatc tctacaaaaa atcttaaaaa 480
tcagtgggac atggtggtgc acatctgtag ttctagctac ttgggagtct gaggcaggaa 540
gattgcttaa gcccaagagt ttgaggtccc tacactccag cctaagcgac agagggagac 600
cttgtctcta aataaataaa ttagttaatt gaatgtccag tcagttgata tatccaaatt 660
cttcccatgg taattttaaa aactttagtc ttaggagagt aaaagtcatg gacataagac 720
ttcttataaa caactcagcc taatgagaaa tagaccctgt atttaagtgt catttaagta 780
tctatttctt cattgatcta ttcatttatt aactcctgta acaatcattt gcagacacct 840
actatgttga ggtagtataa actataaatt caacaagttt gataagggaa ataagagaga 900
ttgagtgaca gcttgaaggg gaggattctt tcaggcctgt gggaccgggt ggtggcatgg 960
agacattatt gtggacttga gggagttaat gtgacagtcc tcgtgtctcc agacactttc 1020
tctctgttag ggaagcaaga tttctatccc cagagtatgt atgtgttatg tctggactgc 1080
agtggcacag aactgtgttc aacgagtgac taccgctctg ctgtgtgccc tgggacttgg 1140
ggttaattga tcaatcattt ctatccagaa ggtaaccatg aggactgacg gaaccagtgt 1200
gtaccaagtg tctgttaagt gtctggtcaa tggttatcca taaagctact gcatggccat 1260
atgtaggaag aatacacacc gtgagcaaat ttttcccacg tgtaactctc acaacaaaat 1320
agcattaaat acttaatgtt tctggctaaa gaccatttca agacttgcag gacaaaaaaa 1380
tagaaaaaat atctgacact caaatggagt tacaaaatta aaacggctga attccccagc 1440
ataaaaaaat atgaagcaag attgaaattt caagactaag tttaatatgg aaaaatacaa 1500
atatgtttga ggcctttcac agagcagcca gcatgaagca accaagaaaa ccacggaaat 1560
aatctggctg cctggaaata gtccggagtc agctgacaca gccacgagag agccctctta 1620
tgcttgtcat aaggggtaaa ggaataattt cagaaaatta catttaaaag agaattatgg 1680
gggaagaaga tgctcccaga ggaaacaaat agtatggatg tgaagagcaa atacaacttt 1740
aacatgtttt gaacttcttg gaaactatgc taagtttagg cattgctagg atttggtatg 1800
atttaatccc cagctttctg ttctaaattt ttgttttctt ttttactctc aaataaatca 1860
tatgctagca ccagctgcaa agttacatat gttgtattag acgatcttcc atgaatacct 1920
aactggaaat tccaagattc agggccatgt gaatctaggc tggctgctta accaaaactt 1980
aatttaattt ttttcgttta ttttaggaaa aaaaattaac gaaaagatgt ttcaagcaac 2040
cagtttccaa tccacgtcag caactatgac atttaatgaa acactgtgag catttagcat 2100
gagagctctg gactcagatg cagggagctt tgctagagaa gggaggaaaa agcaggcatg 2160
atgtggcggg ttgtggggga ctccaaggct ctatttccaa cttccatcag agaacttctg 2220
tttttcacctg gtttttcaaat ttgctttcca aaagggattt tgtttaagta aaggatacag 2280
aggtttataa aagtttgaaa acttctacat tgcaggatgt gcaggctctt gccagatggg 2340
acagtgtatg agactcttcc agggtgacgt cttaggcaat ttcctgtcca atcacagatg 2400
gtcacatgct gctttcctga gttaacctat taactcaccc ttgtttccca ggcctcagtg 2460
gagctaggct tgtcacgtct tcacagtgac tagattccct cacagtcgag tatatctgcc 2520
actccttgac ttttaaaaca tagtctatgt tcaccctcta atatgaagag cccctttcac 2580
tattttcttt gtctgtgctg gagtcacttc agtggcaagt gttctttggt ctctgccgca 2640
ccctccctct gatgcctctg agaagaggat ttccttttcg tgagaatgtc ttcccattct 2700
tcttaccctc ttgaactcac atgttatgcc acttagatga ggaaattgta gttaaataat 2760
tagaaagata tgacttatct caaatcaatc caagatatac tgaagtattg tttatgagta 2820
agatatcagt cttgacgcag aaagaaaaca ggaatccata aggggaggaa agtgttgaaa 2880
agcaaacctg atacagtggg aaaggtggga gacaccataa ggtgctgaag tgataaaaca 2940
ggccagtgtt tctccactgt atgttttcaa taaatgcttc caaggaagga gagtggggca 3000
tgagtagggg agctacagag ataaaccaac ttttcttacc aggaatgcta cagatagcac 3060
```

```
tggtgacacc ggtcaccagt acccaagaca atttaatgtg gaacataagt acaggaatac 3120
acatctttca ttacagagcc atgtatttat tttaatgggc aggagatgct aaataagatc 3180
ttttgaatgg aggaatgcat aaatatatga atgaatgcat acatgaaaga ataaataaat 3240
gctgcctagc accaaggagc gaagatagac tcatatcaag ggaaacaagt atgattaaaa 3300
ataagacccc agagtcacgc tcagtctctt ccagcctttt tcatcatccg gtacattcag 3360
acaagtttca gggaaggatc ctatttgtcc catgataatg atgggcaagg ggtgggggagt 3420
tatctcatac tccgcctgtg gatgaggggt cttctcaggt aaggctctta aatcctaggc 3480
ctgagtaaat tttttcaaat tttattttag acagggtccc tctctgttgc ctaggctgga 3540
gtgcagcggc acaatcacag ctcaatgcag cctcaacctc ccaggcccaa gtgatcctcc 3600
cacctcagcc tcttcagtga ctaggactac aggtgcatga ctccatgctt ggctaacttt 3660
aaaaaatgtt tgtttgtttg tttgtttttt acagagatgg ggtctcacca tgttgcccag 3720
gctgatcttg aactcctggg ctcaagtgat tcccctgcct cggcctcctg aaattctggg 3780
attataggct tgagccacca tgcctggctc tgagtaaaga ttaagggaag ccatggtgct 3840
atcgcaatag ggtaccagcc agcttaacaa aggcagaagg gaacctcaga gaaccccgaa 3900
gagccaccgt aaagtgagtg ctggggggagc tgaacttcag tcagtacagg agccgaacag 3960
ccatcaggtg cgcagtgtta gtaattccac cctctgccct gggagcaagg tgtgtggaga 4020
aacctgtagc actttatgac catcagaacc agcctttttc aaaaagacca tggagtactc 4080
tttgacctgt gtatataaca agaacctttc tcaaatagga aagaaatgaa ttggagaaaa 4140
ccactgttta catggcagag tgtgtctcct tcgcacacat cttgtttgaa gttaatcatg 4200
acattgcaac accaagtgat tccaaataat ctgctaggag tcaccatttc taatgattgc 4260
ctagtctatt catagctaat caagaggatg ttataaagca tgagtcagac acctctggct 4320
ttctggaagg gcaaggactc tatatataca gagggagctt cctagctggg atattggagc 4380
agcaagaggc tgggaagcca tcacttacct tgcactgaga aagaagacaa aggccagt   4438
```

```
<210> 4
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Synthetic

<400> 4
gtggaagctt acacctataa tcccaacact c                                    31

<210> 5
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Synthetic

<400> 5
ctgcctggta ccctattgcg atagcaccat ggc                                  33

<210> 6
<211> 35
```

```
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Synthetic

<400> 6
aaataattag aaagatatga cttatctcaa atcaa                          35


<210> 7
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Synthetic

<400> 7
aaataattag aaaggatatg acttatctca aatcaa                         36


<210> 8
<211> 51
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Synthetic

<400> 8
ttcattgtta atcaagagga tgttataaag catgagtcac accctcagct t         51


<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Synthetic

<400> 9
gttatgccac ttagatgagg                                           20


<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
```

<223> Description of Artificial Sequence:Synthetic

<400> 10
ttcctccct tatggattcc   20

PCT

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C12Q 1/68, C07H 21/04	**A1**	**(11) International Publication Number:** WO 00/32819
		(43) International Publication Date: 8 June 2000 (08.06.00)

(21) International Application Number: PCT/US99/26610

(22) International Filing Date: 10 November 1999 (10.11.99)

(30) Priority Data:
60/110,266   30 November 1998 (30.11.98)   US

30 May 01/30 mo

(71) Applicant *(for all designated States except US)*: TRUSTEES OF DARTMOUTH COLLEGE [US/US]; Technology Transfer Office, 11 Rope Ferry Road #6210, Hanover, NH 03755-1404 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: BRINCKERHOFF, Constance, E. [US/US]; 7 Falcon Lane, Norwich, VT 05055 (US), RUTTER, Joni, L. [US/US]; Balley Road, Thetford, VT 08074 (US).

(74) Agents: LICATA, Jane, Massey et al.; Law Offices of Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053 (US).

(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.

---

(54) Title: METHODS OF DIAGNOSING, PROGNOSTICATING AND TREATING MATRIX METALLOPROTEINASE-1 RELATED DISEASES VIA A MATRIX METALLOPROTEINASE-1 SINGLE NUCLEOTIDE POLYMORPHISM

(57) Abstract

Methods and kits for diagnosing and prognosticating matrix metalloproteinase-1 related disease by detecting a single nucleotide polymorphism in the promoter of the gene are provided. Also provided are methods of identifying agents which inhibit binding of transcriptions factors to the Ets transcription factor binding site created by or resulting from this single nucleotide polymorphism and methods of using these agents to treat matrix metalloproteinase-1 related diseases.